Latest Healthcare It News

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

CONNEQT Health reported a $2.6 million operating cash outflow in the September quarter but secured $2 million through a convertible note, while expecting a $1.6 million R&D tax refund to shore up liquidity.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

CurveBeam AI reports a 33% increase in Q1 FY26 purchase orders, secures A$6.5 million in new funding, and finalizes a strategic joint venture for China distribution and manufacturing rights.

Cann Group Limited has opened a $6.5 million Share Purchase Plan (SPP) alongside a placement, offering shareholders discounted shares with attaching options as it targets significant revenue growth in FY26.

Cann Group Limited (ASX, CAN) launches a $2.5 million Share Purchase Plan offering eligible shareholders discounted shares and attaching options, supporting its recent debt restructure and growth ambitions.

Clever Culture Systems reports a cashflow positive quarter, expanding its pharmaceutical customer base and launching a new contact plate analysis module that promises to drive recurring revenues.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.